Please assess the completion status of the following clinical trial:

Trial Title: Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~For both step I and II:~* Patients with histologically confirmed squamous cell carcinoma of the anal canal~* Aged 18 years or older~* ECOG: 0-1-2~* Adequate contraception in women of child-bearing potential and for men~* Ability to understand and the willingness to sign a written informed consent document.~* HIV-positive patients with T1-2 anal canal tumors, or~* Patients with anal canal tumors not eligible for conventional chemotherapy (for example, due to age and/or co-morbidities)~* Patients who have already started radiotherapy for anal canal cancer~For step II:~* HIV-positive patients with T1, T2 anal canal tumors~* HIV-negative patients not eligible for conventional chemotherapy (for example, due to age and/or co-morbidities)~* HIV-negative patients with T1-2 anal canal cancer~Exclusion Criteria:~For both step I and II:~* Patients receiving any other investigational agents~* Previous treatment with anti-EGFR drugs~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nimotuzumab or other agents used in study.~* Previously treated with pelvic radiotherapy.~* Lesions not suitable for radiotherapy~* Patients with uncontrolled hypercalcemia~* Uncontrolled intercurrent illness~* Pregnant or breast-feeding women~* Any concurrent active malignancy~* Patients with T3-4 anal canal tumors or patients with nodes positive.~Step I:~* HIV-negative patients with anal canal tumors that are judged suitable for current treatment consisting in radiotherapy and 5-FU and MMC chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nimotuzumab (Type: EXPERIMENTAL): Patients will receive weekly injections of Nimotuzumab (200mg/injection) for 12 weeks and standard external beam radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).